103791-0
Infliximab and Infliximab Ab Panel - Serum or Plasma
Active
39803-2 inFLIXimab [Mass/volume] in Serum or Plasma
Part Descriptions
LP35095-6 inFLIXimab
Infliximab is a genetically engineered immunoglobulin 1 murine-human chimeric monoclonal antibody against tumor necrosis factor alpha (TNFα). The murine portion is the part of the antibody that binds to TNFα while the human portion preserves functional immune capacity. Infliximab is used to treat Crohn's disease and, in particular, in treating the closure of intestinal or perianal fistulas in patients with acute intestinal involvement who have been unresponsive to other treatments. TNFα is a cytokine that acts to increase the inflammatory process in CD, RA, psoriasis and spondylarthropathy. The primary mechanism of infliximab is to combine with the inactivate soluble transmembrane TNFα. However, infliximab also modulates TNFα-producing cells through complement fixation of antibody-dependent T lymphocytes and monocytes by binding them to the IgG1 fc portion of infliximab. There is also a subsequent down-regulation of other inflammation-producing cytokines and a reduction of the level of chemokines and endothelial adhesion molecules. Negative side effects of infliximab include fibrostenosing CD and sepsis. PMID: 18360638
Source: Regenstrief LOINC
Fully-Specified Name
- Component
- inFLIXimab
- Property
- MCnc
- Time
- Pt
- System
- Ser/Plas
- Scale
- Qn
- Method
Basic Attributes
- Class
- DRUG/TOX
- Type
- Laboratory
- First Released
- Version 2.15
- Last Updated
- Version 2.73 (MIN)
- Order vs. Observation
- Both
- Common Test Rank Get Info
- 2646
Member of these Panels
| LOINC | Long Common Name |
|---|---|
| 103791-0 | Infliximab and Infliximab Ab Panel - Serum or Plasma |
Member of these Groups Get Info
| LOINC Group | Group Name |
|---|---|
| LG16182-4 | Infliximab| |
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| cs-CZ | Czech (Czechia) | Infliximab: |
| de-AT | German (Austria) | Synonyms: Infliximab |
| de-DE | German (Germany) | Infliximab: |
| el-GR | Greek (Greece) | Ινφλιξιμάμπη: Synonyms: DRUG/TOX MCnc Pt Qn Ινφλιξιμάμπη Ορός Ορός/Πλάσμα Πλάσμα |
| es-ES | Spanish (Spain) | Infliximab: Synonyms: Cuantitativo |
| es-MX | Spanish (Mexico) | inFLIXimab: |
| et-EE | Estonian (Estonia) | Infliksimaab: Synonyms: Juhuslik Kvantitatiivne Plasma Seerum Seerum või plasma |
| fr-CA | French (Canada) | Infliximab: |
| fr-FR | French (France) | Infliximab: |
| fr-BE | French (Belgium) | Infliximab: |
| it-IT | Italian (Italy) | Infliximab: Synonyms: Concentrazione di Massa Livelli farmacologici e tossicologia Plasma Punto nel tempo (episodio) Siero Siero o Plasma |
| ko-KR | Korean (Korea, Republic Of) | Infliximab: |
| nl-NL | Dutch (Netherlands) | infliximab: |
| pl-PL | Polish (Poland) | Infliksymab: |
| pt-BR | Portuguese (Brazil) | InfliximAc: Synonyms: Remicade; |
| ru-RU | Russian (Russian Federation) | Инфликсимаб: Synonyms: Количественный Массовая концентрация Плазма Сыворотка Сыворотка или Плазма Точка во времени; |
| tr-TR | Turkish (Turkey) | İnfliksimab: |
| zh-CN | Chinese (China) | 英利昔单抗: Synonyms: Infliximab 单抗; |
Example Units
| Unit | Source |
|---|---|
| ug/mL | Example UCUM Units |
| mcg/mL | REGENSTRIEF |
72623-2 inFLIXimab Ab [Mass/volume] in Serum or Plasma
Term Description
In the absence of anti-Infliximab antibodies, the Infliximab drug level typically reflects the total Infliximab concentration in serum. In the presence of anti-Infliximab antibodies, the Infliximab drug level typically reflects the antibody-unbound fraction of Infliximab concentration in serum.
Part Descriptions
LP158087-9 inFLIXimab Ab
Antibodies to infliximab (ATI) are detectable in 20% of pediatric and young adult patients taking infliximab. Patients with ATI have reduced levels of infliximab and a higher risk for surgery in patient with inflammatory bowel disease (IBD). When treatment with infliximab is combined with immunomodulators, the likelihood of developing ATI is reduced when compared to using infliximab alone. PMID: 25569737
Source: Regenstrief LOINC
LP35095-6 inFLIXimab
Infliximab is a genetically engineered immunoglobulin 1 murine-human chimeric monoclonal antibody against tumor necrosis factor alpha (TNFα). The murine portion is the part of the antibody that binds to TNFα while the human portion preserves functional immune capacity. Infliximab is used to treat Crohn's disease and, in particular, in treating the closure of intestinal or perianal fistulas in patients with acute intestinal involvement who have been unresponsive to other treatments. TNFα is a cytokine that acts to increase the inflammatory process in CD, RA, psoriasis and spondylarthropathy. The primary mechanism of infliximab is to combine with the inactivate soluble transmembrane TNFα. However, infliximab also modulates TNFα-producing cells through complement fixation of antibody-dependent T lymphocytes and monocytes by binding them to the IgG1 fc portion of infliximab. There is also a subsequent down-regulation of other inflammation-producing cytokines and a reduction of the level of chemokines and endothelial adhesion molecules. Negative side effects of infliximab include fibrostenosing CD and sepsis. PMID: 18360638
Source: Regenstrief LOINC
Fully-Specified Name
- Component
- inFLIXimab Ab
- Property
- MCnc
- Time
- Pt
- System
- Ser/Plas
- Scale
- Qn
- Method
Basic Attributes
- Class
- SERO
- Type
- Laboratory
- First Released
- Version 2.42
- Last Updated
- Version 2.73 (MIN)
- Order vs. Observation
- Both
- Common Test Rank Get Info
- 9310
Member of these Panels
| LOINC | Long Common Name |
|---|---|
| 103791-0 | Infliximab and Infliximab Ab Panel - Serum or Plasma |
Member of these Groups Get Info
| LOINC Group | Group Name |
|---|---|
| LG27918-8 | Infliximab Ab| |
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| cs-CZ | Czech (Czechia) | Infliximab Ab: |
| de-AT | German (Austria) | Synonyms: Infliximab-Antikörper |
| de-DE | German (Germany) | Infliximab Ak: |
| el-GR | Greek (Greece) | Ινφλιξιμάμπη Αντίσωμα: Synonyms: MCnc Pt Qn SERO Αντίσωμα Ινφλιξιμάμπη Ορός Ορός/Πλάσμα Πλάσμα |
| es-ES | Spanish (Spain) | Infliximab Anticuerpos: Synonyms: Cuantitativo |
| es-MX | Spanish (Mexico) | inFLIXimab Ab: |
| et-EE | Estonian (Estonia) | Infliksimaab antikehad: Synonyms: Juhuslik Kvantitatiivne Plasma Seerum Seerum või plasma |
| fr-CA | French (Canada) | Infliximab, Ac: |
| fr-FR | French (France) | Infliximab Ac: |
| fr-BE | French (Belgium) | Infliximab Ac: Synonyms: Anticorps |
| it-IT | Italian (Italy) | Infliximab Ab: Synonyms: anticorpo Concentrazione di Massa Plasma Punto nel tempo (episodio) Siero Siero o Plasma Sierologia (anticorpi e la maggior parte degli ant |
| nl-NL | Dutch (Netherlands) | infliximab As: Synonyms: antistof; |
| pl-PL | Polish (Poland) | Infliksymab Ab: Synonyms: Przeciwciała do Infliksymab |
| ru-RU | Russian (Russian Federation) | Инфликсимаб Ат: Synonyms: Антитело Количественный Массовая концентрация Плазма Сыворотка Сыворотка или Плазма Точка во времени; |
| tr-TR | Turkish (Turkey) | İnfliksimab Ab: Synonyms: Ak |
| zh-CN | Chinese (China) | 英利昔单抗 抗体: Synonyms: Ab; |
Example Units
| Unit | Source |
|---|---|
| ng/mL | Example UCUM Units |